医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

休市中 08-07 16:00:00

972.240

+29.706

+3.15%

最高972.831	最低939.777	成交量7,732万
今开942.658	昨收942.534	日振幅3.51%
总市值0.00	流通市值0.00	总股本0.00
成交额7.63亿	换手率--	流通股本0.00
市净率1.210139	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":972.2398,"timestamp":1786090091709,"preClose":942.5337,"halted":0,"volume":77317197,"delay":0,"changeRate":0.031517,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":29.706116,"latestTime":"08-07 16:00:00","open":942.6577,"high":972.83057,"low":939.77734,"amount":762797028,"amplitude":0.035068,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"pbRate":1.210139,"peRate":10.978996,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2657649942","title":"瑞丽医美(02135)发盈喜 预计中期股东应占溢利约400万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649942","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657649942?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:25","pubTimestamp":1786109150,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞丽医美(02135)发布公告，本集团预期截至2026年6月30日止六个月将录得收益约为人民币1.15亿元，而截至2025年6月30日止六个月则约为人民币8500万元;及本集团预期截至2026年6月30日止六个月将录得归属于母公司股东的盈利约为人民币400万元，而截至2025年6月30日止六个月则录得归属于母公司股东的亏损约为人民币800万元。董事会认为，预期截至2026年6月30日止六个月业绩转亏为盈乃主要由于本集团期内收益增长使得毛利增加约人民币1500万元，该增长主要由(i)医疗美容服务收入增长;及(ii)医疗美容器械产品销售额增加所驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞丽医美(02135)发盈喜 预计中期股东应占溢利约400万元 同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02135","BK1209","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191574560","title":"瑞丽医美预计2026年上半年营收达1.15亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1191574560","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191574560?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:23","pubTimestamp":1786108988,"startTime":"0","endTime":"0","summary":"瑞丽医美（Raily Aesthetic Medicine International）对外披露，其预期截至2026年6月30日的六个月内，公司营收将达到1.15亿元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02135","BK1209","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657383645","title":"复星医药(02196.HK)：盐酸左沙丁胺醇雾化吸入溶液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657383645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657383645?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:19","pubTimestamp":1786105199,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","02196","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162670165","title":"盐酸多巴酚丁胺注射液药品注册申请获国家药监局批准——复星医药","url":"https://stock-news.laohu8.com/highlight/detail?id=1162670165","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162670165?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:05","pubTimestamp":1786104308,"startTime":"0","endTime":"0","summary":"复星医药传来重磅消息：其盐酸多巴酚丁胺注射液的药品注册申请，已正式获得国家药品监督管理局的批准。这一进展，标志着公司在心血管药物领域的布局又迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0188","BK0028","BK0175","BK0012","BK1191","BK1593","02196","BK0060","BK0239","BK0096","BK0183","BK0196","600196","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657864876","title":"复星医药：控股股东复星高科技解除质押1.57亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657864876","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657864876?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:40","pubTimestamp":1786102824,"startTime":"0","endTime":"0","summary":"南财智讯8月7日电，复星医药公告，公司于2026年8月7日接到控股股东上海复星高科技(集团)有限公司通知，其已于2026年8月6日办结所持公司157000000股A股股份的解除质押手续。本次解除质押股份数量为1.57亿股，占其所持公司股份总数的16.33%，占公司股份总数的5.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835369161.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835369161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0012","BK1191","BK0028","BK0239","BK0175","BK0196","BK0183","BK1593","600196","BK1515","BK0187","BK0096","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657487606","title":"复星医药最新公告：子公司盐酸左沙丁胺醇雾化吸入溶液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657487606","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657487606?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:39","pubTimestamp":1786102793,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复星医药(徐州)有限公司的盐酸左沙丁胺醇雾化吸入溶液药品注册申请获国家药监局批准，用于治疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。该药品为本集团自主研发的化学药品，截至2026年6月累计研发投入约566万元。2025年该药品在中国境内销售额约0.73亿元。本次获批将丰富公司产品线，但药品销售受多重因素影响，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700036021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0239","BK0187","BK1515","BK0188","BK0183","BK0175","BK1191","BK0060","BK0012","600196","BK0196","BK0096","BK0028","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657672630","title":"复星医药（600196）披露截至2026年7月31日证券变动月报表，8月6日股价下跌0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657672630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657672630?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:16","pubTimestamp":1786025780,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，复星医药报收于22.76元，较前一交易日下跌0.83%，最新总市值为607.79亿元。该股当日开盘22.96元，最高23.07元，最低22.69元，成交额达4.18亿元，换手率为0.86%。近日，上海复星医药(集团)股份有限公司披露截至2026年7月31日的证券变动月报表。公告显示，公司法定股本无变动，H股和A股的已发行股份及库存股数量与上月结存一致。H股类别中，已发行股份为540,971,500股，库存股为10,969,000股；A股类别中，已发行股份为2,098,582,573股，库存股为19,906,252股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0175","BK0196","BK1515","BK0012","02196","BK1191","BK0188","BK0187","BK1593","BK0239","BK0028","BK0060","161027","BK0096","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657121025","title":"丽丰控股(01125.HK)：公众持股量为14.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657121025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657121025?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:09","pubTimestamp":1785920945,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","01125","BK1240"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596088","title":"中金：维持时代天使(06699.HK)“跑赢行业”评级 上调目标价至104.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596088","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657596088?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:20","pubTimestamp":1785892854,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1587","BK1593","06699","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155870","title":"摩根大通增持时代天使(06699)约8.28万股 每股作价约79.89港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155870","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656155870?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:22","pubTimestamp":1785842544,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月29日，摩根大通增持时代天使(06699)8.2823万股，每股作价79.8894港元，总金额约为661.67万港元。增持后最新持股数目约为1551.34万股，最新持股比例为9.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0203345920.USD","LU0942090050.USD","LU2381873111.SGD","BK4581","LU1244550577.SGD","LU1064131342.USD","LU2242649171.HKD","LU0345770308.USD","PGF","EWH","JPMO","LU1366192091.USD","LU0345770993.USD","LU0964807845.USD","IE00BYXW3230.USD","VFH","LU1988902786.USD","JPX","IE0034235188.USD","UYG","IE00BDCRKT87.USD","KBWB","LU0238689110.USD","LU1162221912.USD","BK1587","LU1629891620.HKD","IXG","LU2357627491.SGD","LU1280957306.USD","FTXO","LU2592432038.USD","TRUF","LU0882574139.USD","LU1668664300.SGD","FNCL","IYF","LU2211815571.USD","IYG","LU2237443978.SGD","BK1593","IE00B1BXHZ80.USD","LU0976567544.SGD","06699","LU2237443382.USD","LU0215105999.USD","LU0820561818.USD","JPO","TFNS","XLF","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656228586","title":"港股异动 | 复锐医疗科技(01696.HK)跌近6% 预计上半年由盈转亏 北美市场面临严峻环境销售下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2656228586","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656228586?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:18","pubTimestamp":1785809919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1585","BK1100","01696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656372073","title":"云南瑞丽—芒市“公路+航空”首单货物出口缅甸","url":"https://stock-news.laohu8.com/highlight/detail?id=2656372073","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656372073?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:12","pubTimestamp":1785766320,"startTime":"0","endTime":"0","summary":"中新网德宏8月3日电 近日，一批重1.44吨、价值12.36万元的跨境电商货物经瑞丽海关查验放行，运输至芒市机场口岸海关监管作业场所，办结转关手续后，货物搭乘航班运往缅甸曼德勒，标志着瑞丽—芒市“公路+航空”陆空联运通道正式开通。芒市海关协同瑞丽海关搭建“公路转航空、陆空双联动”立体化跨境物流网络，企业无需重复申报、重复查验，货物当天即可抵达缅甸，为德宏州跨境电商企业提供一站式验放新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-08-03/doc-inimafqi2572887.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-03/doc-inimafqi2572887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","159231","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656528327","title":"复星医药(02196.HK)：恩格列净二甲双胍缓释片(III)获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656528327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656528327?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:43","pubTimestamp":1785750224,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1593","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188194383","title":"复星医药：聚乙二醇(3350)与电解质散注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1188194383","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188194383?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:39","pubTimestamp":1785749944,"startTime":"0","endTime":"0","summary":"复星医药（FOSUN PHARMA）传来利好消息。其关于“聚乙二醇（3350）与电解质散”的注册申请，已正式获得国家药品监督管理局（NMPA）的批准。此举标志着该药品距离上市迈出了关键一步，有望为相关患者带来新的治疗选择。这一批准不仅彰显了公司在药物研发领域的深厚实力，也进一步丰富了其消化系统疾病治疗的产品线。市场普遍认为，该产品的获批将有助于巩固复星医药在细分市场的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK1593","02196","BK0028","600196","BK0188","BK0096","BK0239","BK0187","BK1191","BK0196","BK0012","BK1515","BK0060","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656278823","title":"复星医药(02196.HK)：复方聚乙二醇(3350)电解质散的药品注册申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656278823","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656278823?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:36","pubTimestamp":1785749803,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","02196","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656326324","title":"复锐医疗科技(01696.HK)发盈警 预计中期股东应占亏损约90万美元至140万美元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2656326324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656326324?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:39","pubTimestamp":1785746371,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01696","BK1585","BK1100","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656032486","title":"复星医药(600196.SH)：恩格列净二甲双胍缓释片(III)获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656032486","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656032486?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:36","pubTimestamp":1785746171,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布公告，近日，公司控股子公司复星万邦(江苏)医药集团有限公司关于恩格列净二甲双胍缓释片(III)的药品注册申请获国家药品监督管理局批准。本次获批适应症为配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["III","02196","BK0012","BK1191","BK4134","BK0188","BK0096","BK1593","BK1515","BK0239","BK0196","BK0060","600196","BK0187","BK0028","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656534355","title":"股市必读：复星医药新发布《复星医药关于控股子公司药品获临床试验批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656534355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656534355?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:34","pubTimestamp":1785695652,"startTime":"0","endTime":"0","summary":"公司公告汇总复星医药关于控股子公司药品获临床试验批准的公告上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药品监督管理局批准，同意其注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗开展临床试验。该治疗方案拟在中国境内开展临床研究，目前全球尚无同类联合用药方案获批上市。HLX43为靶向PD-L1的抗体偶联药物，多项相关临床研究正在全球多个地区开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK1515","BK0183","BK0096","BK0012","BK0060","BK0175","BK0187","600196","BK1191","BK0188","BK0028","02196","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316021","title":"每周股票复盘：复星医药（600196）两基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316021?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:46","pubTimestamp":1785609972,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，复星医药报收于23.23元，较上周的22.67元上涨2.47%。本周，复星医药7月30日盘中最高价报23.29元。公司公告汇总复星医药控股子公司参与设立的天津二期基金和杭州基金已完成私募投资基金备案。复星医药控股子公司复宏汉霖收到国家药品监督管理局批准，同意其注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1191","BK1515","BK0175","BK0188","BK0187","BK1593","BK0183","600196","02196","BK0096","BK0239","BK0060","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655935986","title":"复星医药：控股子公司HLX43联合疗法获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655935986","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655935986?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:32","pubTimestamp":1785486735,"startTime":"0","endTime":"0","summary":"7月31日，复星医药(600196.SH)公告称，公司控股子公司复宏汉霖收到国家药监局批准，同意注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤开展临床试验。截至公告日，全球尚无同类联合用药获批上市。截至2026年6月，该治疗方案累计研发投入约815万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828342369.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828342369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0188","BK0012","BK0196","BK0239","02196","BK0028","PSYK","IBBQ","BK0187","600196","BK0175","BK0060","MDTX","IBBJ","BK0183","BK1593","BK0096","BK1191","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}